Atul Ltd 2017-18

47 Pharmaceuticals and Aromatics – I Product groups: API intermediates, Active Pharmaceutical Ingredients, Others The products falling under these product groups are used by customers belonging to Pharmaceutical industry for various therapeutic categories, such as anti-depressant, anti-diabetic, anti-infective, anti-retroviral and cardiovascular. The product groups comprise about 72 products. Carbonates, chloroformates, isocyanates and organic ureas are some of the key classes of products. During 2017-18, sales increased by 7% from ` 342 cr to ` 367 cr. Sales in India increased by 22% from ` 178 cr to ` 218 cr. Sales outside India decreased by 9% from ` 164 cr to ` 149 cr and formed 41% of the total. Growth on account of volume was 6%. The Company completed 1 project and undertook 1 project for implementation. Atul Bioscience Ltd (ABL), a 100% subsidiary company, focused on production of advanced API intermediates, increased its sales by 33% from ` 57 cr to ` 76 cr, primarily because of volume; it undertook 2 debottlenecking projects for implementation. The size of the world Pharmaceutical industry is estimated at US$ 1.75 tn, of which the conventional pharmaceutical segment is estimated to be US$ 1.3 tn. Of this, the size of the world API industry is estimated to be US$ 160 bn. There are about 20 major companies which dominate the world marketplace. The main user industry, namely, Pharmaceutical, is growing well because of increasing awareness about diseases and health. The Company along with ABL will participate in this growth by i) widening its market reach, ii) increasing its manufacturing efficiencies, iii) generating and adding capacities, iv) introducing new products and v) forming long-term strategic alliances with other companies. The prices of some products may come down in a short time. Fluctuations in foreign exchange may impact sales realisations.